As we close out an eventful and transformative year, I am pleased to share some reflections on our progress and highlight the milestones that position MVMD for a strong 2025.
This year, we made meaningful strides across our three core business areas — Nutraceuticals, Agriculture, and Husbandry Animals/Aquatic Species. Our numerous advancements across the business are a testament to the dedication of our team, the strength of our partnerships, and the innovative technologies at the heart of MVMD.
This shareholder update provides you with a highlight of some of our key activities and progress that were published in our year-end update media release that was sent out this morning. I encourage you to read the full release on our website at MVMD.com.
NUTRACEUTICALS
In 2024, our Quicksome™ technology continued to demonstrate its disruptive potential in the nutraceutical space. Our formulation and manufacturing teams have worked hard this year on delivering proprietary formulations designed to enhance bioavailability, reduce variability, and achieve significant dose-sparing benefits across a wide variety of active ingredients.
• Opioid Use Disorder (OUD) Therapy: We developed a proprietary sublingual adjunct therapy formulation, ready for clinical trials in 2025.
• Fenugreek Testosterone Product: Clinical testing is underway, showing promise in supporting muscle mass, energy, and vitality.
• Circadian Wellness Partnership: The launch of Eons Deeper Sleep and Eons Dialed marked significant milestones, with royalty revenues anticipated in Q1 2025.
• "Mountains Of..." Brand: Our trademark protection and unique formulation offerings support our business development initiatives for future nutraceutical product licensing and partnerships.
AGRICULTURE
The Agrarius platform has continued to demonstrate its transformative potential in enhancing agricultural productivity and sustainability, making meaningful advancements in key regions.
• Agrarius is now approved and saleable in the European Union, Canada, Colombia, Brazil, Panama, Peru, and the United States, with additional registrations pending in Costa Rica, Uruguay, Chile, Mexico, and South Africa.
• Trials have consistently validated yield improvements, enhanced plant resilience, and superior disease management outcomes.
• The Agrarius Performance Guarantee Program has successfully reduced adoption barriers, with contracted trials in Montana and Illinois (U.S.) and Alberta (Canada) delivering measurable results. Expanding program to key South America markets.
• Strategic partnerships in Latin America are advancing, with revenue from contracted farms expected early in 2025.
• First product import trial into Brazil has been successfully completed, paving the way for large-scale shipments anticipated in 2025.
HUSBANDRY ANIMALS / AQUATIC SPECIES
Although a slower start than we anticipated, our Soluvec™ technology continues to show strong promise, with commercialization advancing steadily.
• Initial sales of Soluvec™ 1% coated fish feed in Bangladesh reached 100 tonnes despite early-year disruptions.
• Manufacturing resumed in late 2024, with continued expansion planned into 2025.
• Global licensing discussions and patent filings in 12 additional markets demonstrate growing international interest.
LOOKING AHEAD
With revenue streams from nutraceutical partnerships, expanding Agrarius commercialization, and a growing international presence for Soluvec™, I truly believe we are building a resilient and scalable business model.
Thank you for your continued support and trust in MVMD. I am excited about the opportunities ahead and confident in our ability to make a meaningful impact towards our mission of “More Life”.
Wishing you all a healthy and prosperous 2025.
